CD19 and neoplasm: Prior to the addition of CD19 CAR T cells, we pretreated tumor cells with 30 nM panobinostat or 0.5 μM entinostat for 24 h, both of which showed no effect on the viability of Raji and Daudi cells (Supplemental Fig. 4a–d).